Chinese facility changes hands from GSK to Fosun Pharmaceutical

Published: 10-Jul-2019
Finance

The deal has been reported to be worth US$36 million

A manufacturing facility in Suzhou, China has been purchased by Fosun Pharmaceuticals from GSK. The deal has been reported to be worth US$36 million, according to a company state.

The new owners of the facility west of Shanghai said that the plant produced a revenue of $94.4m in 2018.

The deal will also allow YaoPharma, Fosun's Chongqing unit, to acquire all production facilities and authorisations for the GSK plant's chronic hepatitis B drug lamivudine.

The news of this sale comes as GSK announced the opening of its new API continuous manufacturing facility in Singapore. This will be a big shift in manufacturing focus in the Asian region for the pharma giant.

  • Companies:
  • GlaxoSmithKline
  • Fosun
See more

You may also like

Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Read more
Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site

Trending Articles

  1. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  2. Sales Account Manager - Print, Online and Event Sales - London - £38,000/yr - £40,000/yr This is an exciting role for an Account Manager to join the Science portfolio of HPCi Media. Please get in touch with alib@hpcimedia.com via email with a CV and covering letter
  3. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  4. SHL to expand Taiwan production facilities in US$40m investment To meet growing demand in the biologic injectable market
  5. Get ahead of the curve with a subscription Keep abreast of significant pharmaceutical developments around the world

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site
Finance

Sareum notes completion of Sierra Oncology’s acquisition by GSK

Sareum Holdings, the specialist drug development company, notes that GSK has completed its acquisition of Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), for $1.9 billion in cash
Finance

GSK shingles vaccine available in the UK

The UK launch of the vaccine follows "unanticipated demand," the company says
Finance

Medicines Manufacturing Innovation Centre completes construction

The internal fit out of the facility is planned to be completed in early 2022
Finance

Sanofi and GSK in discussions with EU to supply COVID-19 vaccine

Sanofi and GSK in advanced discussions with the European Union to supply up to 300 million doses of COVID-19 vaccine
Ingredients

Sanofi and GSK team up on adjuvanted COVID-19 vaccine

The companies have entered into a Material Transfer Agreement to enable them to start working together immediately
Ingredients

GSK invests $250m in coronavirus R&D agreement

GSK has made an equity investment in Vir Biotechnology to gain access to its proprietary monoclonal antibody platform technology
Subscribe now